Provided by Tiger Trade Technology Pte. Ltd.

Solid Biosciences

6.29
-0.0200-0.32%
Post-market: 6.290.00000.00%16:10 EST
Volume:754.89K
Turnover:4.67M
Market Cap:490.06M
PE:-2.54
High:6.32
Open:6.25
Low:5.95
Close:6.31
52wk High:7.37
52wk Low:2.41
Shares:77.91M
Float Shares:37.61M
Volume Ratio:0.90
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4800
EPS(LYR):-3.0550
ROE:-86.83%
ROA:-43.67%
PB:2.25
PE(LYR):-2.06

Loading ...

Solid Biosciences Inc - Grants Andelyn License to Utilize Aav-Slb101

THOMSON REUTERS
·
Nov 17, 2025

Solid Biosciences Director Ilan Ganot Reports Sale of Common Shares

Reuters
·
Nov 14, 2025

Solid Biosciences to Participate at Upcoming Investor Conferences

GlobeNewswire
·
Nov 11, 2025

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

GlobeNewswire
·
Nov 06, 2025

Solid Biosciences Is Maintained at Buy by Citigroup

Dow Jones
·
Nov 06, 2025

Solid Biosciences Is Maintained at Overweight by JP Morgan

Dow Jones
·
Nov 06, 2025

Solid Biosciences (SLDB) Receives a Buy from J.P. Morgan

TIPRANKS
·
Nov 05, 2025

Solid Biosciences (SLDB) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Nov 05, 2025

Solid Biosciences Inc : Citigroup Cuts Target Price to $14 From $16

THOMSON REUTERS
·
Nov 05, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Nov 05, 2025

Solid Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 04, 2025

Solid Biosciences’ SGT-003 Therapy Shows Promising Efficacy and Safety, Earning a Buy Rating

TIPRANKS
·
Nov 04, 2025

Solid Biosciences price target lowered to $9 from $10 at Barclays

TIPRANKS
·
Nov 04, 2025

Solid Biosciences Reports Q3 2025 Results and Clinical Progress

TIPRANKS
·
Nov 04, 2025

Solid Biosciences Reports Positive Interim Data on SGT-003

TIPRANKS
·
Nov 04, 2025

Solid Biosciences Q3 EPS $(0.48) Misses $(0.43) Estimate

Benzinga
·
Nov 04, 2025

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on Inspire Duchenne Clinical Trial Progress and Planned Regulatory Discussions

THOMSON REUTERS
·
Nov 04, 2025

Press Release: Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Dow Jones
·
Nov 04, 2025

Solid Biosciences Inc expected to post a loss of 44 cents a share - Earnings Preview

Reuters
·
Nov 01, 2025

Solid Biosciences to Participate at Upcoming Investor Conferences

GlobeNewswire
·
Oct 30, 2025